Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Having a parent or sibling with NAFLD-related cirrhosis dramatically increases the risk.
Five Liver Meeting takeaways for viral hepatitis advocates in the United States.
Clinical trial and real-world treatment results are comparable.
Highlights from the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston
The fact that half had been treated before and all had cirrhosis made the group traditionally difficult to treat.
The once-daily investigational hepatitis C virus (HCV) combination tablet will likely be approved in 2017.
The drug improved several measures of liver disease severity among those with non-alcoholic steatohepatitis in a clinical trial.
Today’s teenagers are more likely to suffer from non-alcoholic steatophepatitis (NASH).
Biological members of the nuclear families of those with NAFLD are much more likely to have the condition as well.
The use of one of two nucleic acid polymers dramatically reduced hep B viral load among those with e-antigen-negative hepatitis B virus.
The relative simplicity of treating the virus with today’s treatments often means nonspecialist prescribers may provide sufficient care.
Individuals who develop liver cancer shortly after successful hepatitis C virus (HCV) treatment may have more aggressive cases.
Those who ate more meals per day and did not skip breakfast or lunch were less likely to develop nonalcoholic fatty liver disease.
However, the new triple combo’s results among those with genotype 1a of hep C were subpar.
Eight weeks of treatment had high cure rates among this hardest-to-treat group.
Efforts to test the highest-risk cohort and get those who test positive into care and treatment for the virus have been woefully inadequate.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.